Phil Campbell
Research Professor, Biomedical Engineering, Engineering Research Accelerator
Courtesy Appointments, Biological Sciences, Materials Science and Engineering
Research Professor, Biomedical Engineering, Engineering Research Accelerator
Courtesy Appointments, Biological Sciences, Materials Science and Engineering
Phillip Campbell is a Research Professor in the Biomedical Engineering Department and the Engineering Research Accelerator at Carnegie Mellon University. He has courtesy appointments in the Biological Sciences and the Mechanical Engineering Departments. Campbell has over 25 years of experience in multidisciplinary research with both engineers and clinicians to develop unique solutions to a wide variety of complex biomedical problems, including the development of natural-based biomaterials, implant biocompatibility, and tissue engineering. One of his overarching research themes involves understanding and engineering the cellular microenvironment from an endocrine point of view, both in vitro and in vivo. The study encompasses growth factor interstitial transport, interactions with receptors and non-receptor binding proteins, immobilization and proteolytic processing of extracellular matrix bound growth factors and other signaling molecules, and live cell and animal imaging. His research has taken advantage of biopatterned microenvironments to spatially deliver signaling molecules to spatially control cell behavior in vitro and tissue formation in vivo toward musculoskeletal, cardiac, immunological, and cancer applications.
1988 Ph.D., Physiology, Pennsylvania State University
1981 MS, Animal Science, Auburn University
1978 BS, Animal Science, Auburn University
CMU Engineering
A CMU-led project team secured an award of up to $42M from ARPA-H to accelerate the development of implantable bioelectronic devices that deliver patient-specific therapy and monitor disease status.
CMU Engineering
A CMU-led team of researchers has secured an award of up to $34.9 million from ARPA-H to develop a new bioelectric medicine-based treatment for obesity and Type 2 diabetes patients.
NIH
BME’s Charlie Ren and Phil Campbell have received a five-year, $3.5 million Bioengineering Partnerships with Industry (BPI) grant from the NIH, in partnership with David Vorp of the University of Pittsburgh.
University of Pittsburgh
The American Heart Association’s 2023 Collaborative Sciences Award will be investigated by a multi-institutional team of researchers, including BME’s Phil Campbell and Charlie Ren.
CMU Engineering
Two CMU materials science and biomedical engineering alumni are at the forefront of the development of an airless basketball made through additive manufacturing techniques.
CMU Engineering
Researchers engineer a hybrid system that stabilizes curcumin to target skin diseases.
CMU Engineering
3D printed ice isn’t as magical as in the movie Frozen, but it has wonderful potential for biomedical engineering and advanced manufacturing.
CMU Engineering
An interdisciplinary group of faculty from Carnegie Mellon has licensed a proprietary platform for bioengineering exosomes for drug delivery to Coya Therapeutics, Inc.
CMU Engineering
Phil Campbell and Charlie Ren present a strategy to spatially control extracellular vesicles and keep them resolute under controlled conditions.
CMU Engineering
Mayo Clinic and Carnegie Mellon University announced today a research agreement to transform organ transplantation. The institutions will bioengineer innovative approaches to address current barriers in organ transplantation.
CMU Engineering
New research from Carnegie Mellon University and UPMC explores an innovative case for exosomes: delivering growth factors like bone morphogenetic proteins (BMPs) for bone healing.
CMU Engineering
In recent years, there has been an explosion in exosome research. CMU researchers have created an “all-purpose” platform for using exosomes for drug delivery in living organisms.